Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bruce E. Strober
Updates in PsO Sequencing and Future Research
As the psoriasis (PsO) armamentarium has grown, the question of how to sequence therapies — both initially and following partial or inadequate response — has become increasingly consequential. A patient's response to an IL-23 directed therapy, whether injectable or oral, provides direct in vivo information about the contribution of the IL-23 pathway to their individual disease.
Risankizumab vs Icotrokinra for Psoriasis
Published on: Bruce Strober, MD, PhD, introduces a practical framework for determining when differences in efficacy between psoriasis treatments are clinically meaningful. With multiple high-performing agents now available for moderate to severe psoriasis (PsO), clinicians increasingly face a decision not between effective and ineffective therapy but among options that differ in mechanism, route, dosing schedule, and depth of long-term evidence.
Comparing IL-23 Inhibitors — Dosing Intervals, Radiographic Data, and Long-Term Drug Survival
Published on: Bruce Strober, MD, PhD, compares agents within the IL-23 inhibitor class on dosing schedule and joint outcome data, and explains why long-term drug survival has become a central consideration in biologic selection for psoriasis.
Patient-Level Treatment Drivers in Psoriasis
Published on: Bruce Strober, MD, PhD, examines patient preference for oral versus injectable therapy. Effective psoriasis (PsO) management increasingly depends on a treatment selection framework that extends beyond skin severity to encompass the full clinical and contextual profile of the individual patient. Route of administration is among the most practically influential of these factors.
Treatment Algorithms in The Modern Psoriasis Landscape
Published on: New oral icatokinra shifts psoriasis care with PASI 90 rates, once-daily dosing, and no blood-test monitoring—challenging biologics. The treatment of moderate to severe psoriasis (PsO) has been transformed by biologic agents targeting the IL-23/IL-17 axis — a cytokine cascade now well established as central to psoriatic inflammation.
Patient-Level Treatment Drivers — Route of Administration, Psoriatic Arthritis, and Comorbidity Considerations
Published on: Oral therapies offer convenience, but biologics deliver faster, stronger results; experts weigh psoriatic arthritis, dosing schedules, safety profiles, and IL-17 vs IL-23 choices. Strober examines how patient preference for oral versus injectable therapy and the presence and pattern of psoriatic arthritis.
Biologics Versus Oral Small Molecules — Redefining the Psoriasis Treatment Hierarchy
Published on: Icotrakinra brings once-daily oral IL‑23 receptor blockade with near‑biologic psoriasis clearance, expanding injection-free options for treatment-seeking patients. Strober explains how the arrival of icotrakinra, a first-in-class oral IL-23 receptor blocker, has meaningfully shifted the psoriasis treatment paradigm.
Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis
Published on: , A panel of dermatologists have a comprehensive discussion on exciting developments in the treatment of plaque psoriasis, focusing on treatment approaches, patient monitoring strategies, and recent clinical trial data. To watch the video series component of this episode, click here.
Systemic Therapies for Plaque Psoriasis
Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis - Episode 2 Published on: , Dermatologists have a comprehensive discussion on systemic therapies for the treatment of plaque psoriasis, covering monitoring practices, and long term efficacy data for novel oral agent deucravacitinib. 00:05 Monitoring Systemic Therapy in Plaque Psoriasis 03:34 New Oral Systemic Therapies for Plaque Psoriasis 10:05 Efficacy Data on Deucravacitinib
Plaque Psoriasis: Comorbidities, Classification, and Testing Practices
Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis - Episode 1 Plaque Psoriasis: Comorbidities, Classification, and Testing Practices Published on: June 25, 2024 Linda Stein Gold, MD, and Bruce Strober, MD PhD, discuss classification and monitoring practices for patients with plaque psoriasis. 1:09 Comorbidities in Plaque Psoriasis 5:11 Classifying the Severity of Plaque Psoriasis 8:30 Laboratory Tests for Systemic Therapy
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
INTRODUCTION The Janus kinase (JAK)-signal transducer and activator of transcription pathways play a major role in cytokine signalling in normal cellular processes and in immune-mediated diseases such as psoriasis.1, 2 JAK1,2,3 inhibitors are efficacious in patients with moderate-to-severe plaque psoriasis; however, JAK1,2,3 inhibitors are also associated with creatine phosphokinase (CPK) elevations, hyperlipidaemia and minimal hematologic abnormalities.3, 4 Therefore, it is important to...
Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil™ 2 study | Future Rare Diseases
What is this study about? Generalized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been approved to treat worsening GPP (known as flares) in many countries. However, it was not known if spesolimab could prevent the symptoms of GPP.
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
Key Points Question What constituted meaningful within-patient score improvement on the Psoriasis Symptoms and Signs Diary (PSSD) in a phase 3 trial among patients with psoriasis?
The Future of Plaque Psoriasis Therapy
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 9 Published on: , , Expert dermatologists highlight the future of plaque psoriasis treatment, commenting on advances in therapy as well as increasing access to treatment. Bruce Strober, MD, PhD, FAAD: Ben, what are some of the pipeline therapeutics, future developments that you’re excited about with regard to psoriasis?
Using IL-23 Inhibitors in Clinical Practice for Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 8 Published on: , , Benjamin Lockshin, MD, FAAD; and Jennifer Soung, MD, share their experience with IL-23 inhibitors for the treatment of plaque psoriasis in clinical practice. Bruce Strober, MD, PhD, FAAD: Ben, can you share with me an anecdotal case of success that involves an IL-23 inhibitor, one that really was impactful for you?
Selecting IL-23 Inhibitors for Treating Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 7 Published on: , , Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis. Bruce Strober, MD, PhD, FAAD: So, Ben, this is a tougher question. How do you go about selecting among the various IL-23 inhibitors we have at our disposal?
Shifting the Paradigm for Plaque Psoriasis Therapy
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 6 Published on: , , Expert dermatologists discuss the paradigm shift occurring in the management of plaque psoriasis as a result of the expanded array of treatment options. Bruce Strober, MD, PhD, FAAD: Jennifer, is there a paradigm shift occurring right now that you can foresee that defines how we approach psoriasis in 2023 moving into 2024 or from the way we did in 2015 to [20]18?
Head-to-Head Studies for Plaque Psoriasis Therapies
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 5 Published on: , , Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast. Bruce Strober, MD, PhD, FAAD: Jennifer, we have a lot of head-to-head studies between IL-23 inhibitors and other medications with different mechanisms of action.
Considering Safety of IL-23 Inhibitors for Plaque Psoriasis With The Patient
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 4 Published on: , , Expert dermatologist comments on initiating conversations about the safety of IL-23 inhibitors with patients with plaque psoriasis, highlighting biologic-naive patients.
Efficacy of IL-23 Inhibitors for Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 3 Published on: , , Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment. Bruce Strober, MD, PhD, FAAD: What have we learned about the efficacy of IL-23 inhibitors over the 5 to 7 years we’ve had them on the market?
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
Main Article Content Keywords bimekizumab, psoriasis, safety, mental health, suicide, suicidality, plaque psoriasis, depression, clinical trial Abstract References 1. Kurd SK et al. Arch Dermatol 2010;146:891–5; 2. Kroenke K et al. J Gen Intern Med 2001;16:606–13; 3. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790; 4. Reich K et al. Lancet 2021;397:487–98, NCT03370133; 5. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992; 6. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747; 7.
Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].
Efficacy of Secukinumab in Patients With Mild to Moderate Psoriasis: A Pooled Analysis of 6 Phase 3 Studies
Main Article Content Keywords psoriasis, secukinumab Abstract References 1. Langley RG, et al. N Engl J Med. 2014;371(4):326-338. 2. McInnes IB, et al. Lancet. 2020;395(10235):1496-1505. 3. McInnes IB, et al. Rheumatology (Oxford). 2017;56(11):1993-2003. 4. Nash P, et al. Arthritis Res Ther. 2018;20(1):47. 5. Kivitz A, et al. Rheumatol Ther. 2019;(6):393-407. 6. Mease PJ, et al. Ann Rheum Dis. 2018;77(6):890-897. 7. Gottlieb A, et al. J Am Acad Dermatol. 2017;76(1):70-80.
Approaches to Treating Plaque Psoriasis
Taking the Path to Clearer Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis - Episode 2 Published on: , , Expert dermatologists share how the understanding of the pathophysiology of plaque psoriasis guides approaches to therapy. Bruce Strober, MD, PhD, FAAD: So Ben, we have a lot of different biologics now, more so than ever. There are multiple mechanisms of action [MOAs]. Basically, we understand how to approach psoriasis because we understand the pathophysiology.
Impact of Plaque Psoriasis on Quality of Life
Bruce Strober, MD, PhD, FAAD: Hello and welcome to this HCPLive® Peers & Perspectives [episode] titled “Taking the Path to Clear Skin: Targeted Treatment Through IL-23 Inhibition for Plaque Psoriasis.” I am Dr Bruce Strober, clinical professor of dermatology at Yale University School of Medicine [in New Haven, Connecticut].
Risankizumab maintains psoriasis clearance in both bio-naïve, bio-experienced patients
Source/Disclosures Disclosures: Strober reports having financial relationships with AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Cara, Connect Biopharma, CorEvitas Psoriasis Registry, Dermavant, Dermira, EPI Health, Evelo Biosciences, Janssen, Journal of Psoriasis and Psoriatic Arthritis, Leo, Eli Lilly, Incyte, Janssen, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, UCB Pharma, Sun Pharma,...
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
ImmunotherapyAhead of Print Plain Language Summary of PublicationOpen Access , , , , , , , , , , , , , , & Abstract What is this summary about? This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis. Plaque psoriasis appears on the body as dry, discolored, patches of skin that can be flaky and covered in scales.
Future Directions in the Use of TYK2 Inhibitors for the Treatment of Psoriasis
Linda Stein Gold, MD: I just want to touch on the fact that there are some other TYK2 [tyrosine kinase 2] inhibitors that are in clinical trials, not so far along, but can you comment on that? Bruce Strober, MD, PhD: I actually think the approval of deucravacitinib has opened the door for this entire new class to be developed. I think this is not going to be our last TYK2 inhibitor.
Potential Uses for TYK2 Inhibitor Regiments in Plaque Psoriasis and Psoriatic Arthritis
Linda Stein Gold, MD: So we’ve gotten the patient the drug. We’ve gone through. We’ve done everything we need to. The patient’s on the drug. They have some breakthrough areas or maybe it’s the first 4 to 8 weeks where they’re seeing some clearing, but they’re not clear. Do you have any qualms in adding potentially a topical in addition to something like deucravacitinib?
Navigating Treatment Access Challenges in Patients With Plaque Psoriasis
Exploring Novel TYK2-Targeted Therapies for Plaque Psoriasis - Episode 7 Linda Stein Gold, MD, and Bruce Strober, MD, PhD, share considerations for ensuring that patients on Medicare and Medicaid receive the appropriate medication. Linda Stein Gold, MD: Now that we’ve talked about the efficacy, the safety, do you have any tips in terms of getting patients the medication, including deucravacitinib, that you want them to have?
Expert Insights on Therapeutic Selection for the Treatment of Plaque Psoriasis
Linda Stein Gold, MD: This sounds like a really great new tool in our treatment armamentarium. But when we have those patients who come in now with moderate to severe scalp psoriasis or psoriasis in a sensitive area, we have so many tools. When would you think about using an oral agent like deucravacitinib? If a patient walks in and says, “I’ve used topical therapy. I have maybe 15% body surface area. Maybe I have a little bit on my scalp. Maybe it kind of comes down onto my forehead.
Laboratory Evaluations for TYK2 Inhibitors in the Treatment of Psoriasis
Linda Stein Gold, MD: In terms of getting a patient started on deucravacitinib, TB [tuberculosis] test? Bruce Strober, MD, PhD: Yes. That is part of the label and it’s part of the label for all of our immunosuppressive drugs. So, a QuantiFERON Gold is what I get for every patient who walks in the door who has bad psoriasis. Linda Stein Gold, MD: Then, in terms of laboratory monitoring, I’m just practically the ABCs of starting a patient on deucravacitinib, TB test, yes.
Reviewing the Safety Profile of Deucravacitnib
Linda Stein Gold, MD: You talked to us about the mechanism of action and what we should expect, blocking TYK2 should not have the downstream effect on hematopoiesis or other metabolic…. In the clinical trials, did that hold true? Bruce Strober, MD, PhD: Yes. The issues you are concerned with when you use what’s called a JAK inhibitor, which TYK2 is a JAK kinase inhibitor, are major adverse cardiovascular events [MACE], thromboembolic events, cancer, herpes zoster, serious infections.
Understanding the Differences Between Inhibiting TYK2 Versus Traditional JAK Inhibition
Exploring Novel TYK2-Targeted Therapies for Plaque Psoriasis - Episode 2 Understanding the Differences Between Inhibiting TYK2 Versus Traditional JAK Inhibition Thought leaders talk about the approval and integration of a first-in-class agent into the treatment armamentarium. They also review the mechanisms of TYK2 inhibition.
Psoriasis Treatment Landscape Overview and Assessment of Efficacy
Exploring Novel TYK2-Targeted Therapies for Plaque Psoriasis - Episode 1 Psoriasis Treatment Landscape Overview and Assessment of Efficacy Linda Stein Gold, MD, and Bruce Strober, MD, PhD, assess the efficacy of traditional and newer treatment options for psoriasis. They also discuss therapeutic targets and the goals of therapy.
Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy
Main Article Content Keywords psoriasis, real-world evidence, treatment switching Abstract Introduction: Better understanding of the relationship between quality of life and treatment patterns in psoriasis may help guide therapeutic algorithms. This study evaluated the association between patient-reported disease burden and treatment switching from nonbiologic to biologic therapy in patients with plaque psoriasis enrolled in the CorEvitas Psoriasis Registry.
Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Main Article Content Keywords Tapinarof, Aryl Hydrocarbon Receptor Agonist, Remittive Effect, Efficacy, Long-term Therapy, Plaque Psoriasis, Topical References 1. Nowowiejska J, et al. Dermatol Ther (Heidelb). 2022;12:385–406. 2. Langley RGB, et al. Ann Rheum Dis. 2005;64(suppl 2):ii18–23. 3. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–67. 4. Tian D, Lai Y. J Invest Dermatol. 2022;2:100116. https://doi.org/10.1016/j.xjidi.2022.100116. 5. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432–70. 6.
JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
Introduction Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder with a heterogeneous clinical presentation and the cardinal symptom of itch, that results in significant patient burden and a significant decrease in patient’s quality of life. 1 JAK inhibitors in the treatment of atopic dermatitis.
Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
Main Article Content Keywords bimekizumab, psoriasis, moderate to severe, phase 3, clinical trial, pooled results, bodyweight, dosing References 1. Puig L. J Eur Acad Dermatol 2011;25:1,007–011 2. Warren RB. N Engl J Med 2021;385:130–41 3. Reich K. Lancet 2021;397:487–98 4. Reich K. N Engl J Med 2021;385:142–52 5. Gordon KB.
Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes | SKIN The Journal of Cutaneous Medicine
Main Article Content Keywords psoriasis, machine learning, clinical utility, biomarkers, transcriptomics, biologics Abstract Objective: This study (MATCH) was designed to assess the clinical utility of a machine-learning based tool (Mind.Px) that predicts patient response to the most common biologic drug classes used in the management of psoriasis patients. Methods: The MATCH study was designed to assess Mind.Px utility in physician decision making and patient outcomes.
Bimekizumab maintains efficacy through 3 years in psoriasis
Source/Disclosures Source: Strober B, et al. Poster. Bimekizumab maintenance of response through 3 years in patients with moderate to severe plaque psoriasis who responded at week 16: Results from the BE BRIGHT open label extension trial. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 7-10, 2022; Milan. Disclosures: These studies were funded by UCB Pharma. Medical writing support provided by Costello Medical. Source/Disclosures Source: Strober B, et al. Poster.
Psoriasis Oral Agents: What to Know to Prescribe Like a Pro
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel This transcript has been edited for clarity. Steven R. Feldman, MD, PhD: Welcome to Medscape InDiscussion on psoriasis. I'm your host, Dr Steve Feldman. For years we relied on older immunosuppressive drugs like methotrexate and cyclosporine to treat extensive psoriasis.
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
Background Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with mild to severe plaque psoriasis. Objective To assess long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof. Methods Patients completing the 12-week trials were eligible for 40-weeks’ open-label treatment and 4-weeks’ follow-up.
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Main Article Content Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Linda Stein Gold Henry Ford Health System, Detroit, MI, USA Robert Bissonnette Innovaderm Research, Montreal, QC, Canada April Armstrong University of Southern California Andrew Blauvelt Oregon Medical Research Center, Portland, OR, USA Leon Kircik Skin Sciences PLLC Philip Brown Dermavant Sciences, Inc., Morrisville, NC, USA Anna Tallman Dermavant Sciences, Inc.,...
Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis
Figure 1. Disease Control Assessed Using the Patient-Reported Atopic Dermatitis Control Tool (ADCT) Adequate disease control reflects a total ADCT score lower than 7. aP < .001 vs baseline. Figure 2.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Related Articles Abstract Background Tapinarof cream is a topical aryl hydrocarbon receptor–modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin. Methods Download a PDF of the Research Summary. We conducted two identical phase 3 randomized trials of tapinarof in patients with mild-to-severe plaque psoriasis.
Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies | SKIN The Journal of Cutaneous Medicine
Main Article Content April Armstrong Keck School of Medicine at University of Southern California, Los Angeles, CA, USA Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Kenneth Gordon Medical College of Wisconsin, Milwaukee, WI, USA Joe Zhuo Bristol Myers Squibb, Princeton, NJ, USA Brandon Becker Bristol Myers Squibb, Princeton, NJ, USA Renata Kisa Bristol Myers Squibb, Princeton, NJ, USA John Throup Bristol Myers Squibb, Princeton, NJ,...
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Main Article Content Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Linda Stein Gold Henry Ford Health System, Detroit, MI, USA Robert Bissonnette Innovaderm Research Inc., Montreal, QC, Canada April Armstrong Keck School of Medicine at University of Southern California, Los Angeles, CA, USA Andrew Blauvelt Oregon Medical Research Center, Portland, OR, USA Philip Brown Dermavant Sciences, Inc., Morrisville, NC, USA Leon Kircik Mount...
Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial | SKIN The Journal of Cutaneous Medicine
Main Article Content Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Akihiko Asahina The Jikei University School of Medicine, Tokyo, Japan; Ulrich Mrowietz Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig- Holstein, Campus Kiel, Germany Mark Lebwohl Peter Foley The University of Melbourne, St. Vincent’s Hospital Melbourne, Fitzroy and Probity Medical Research Inc., Skin Health Institute, Carlton, Victoria,...
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
Soligenix, Inc. will be expanding synthetic hypericin development under the research name SGX302 into psoriasis. The company made this move after the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bruce E.
Contact Bruce E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack